Rtp801l sirna compounds and methods of use thereof
AssigneeQuark Pharmaceuticals, Inc.
InventorsElena Feinstein, Igor Mett, Hagar Kalinski
Life of this patent
Estimating the term…
Abstract
The invention provides chemically modified siRNA oligonucleotides that target RTP801L, compositions comprising same and to the use of such molecules to treat, inter alia, respiratory diseases including acute and chronic pulmonary disorders, eye diseases including glaucoma and ION, microvascular disorders, angiogenesis- and apoptosis-related conditions, and hearing impairments.
Claims21
1-28. (canceled)
A method for providing neuroprotection in a patient in need thereof, comprising administering to the patient a therapeutically effective dose of a RTP801L inhibitor, thereby providing neuroprotection in the patient.
A method for treating a neurodegenerative disease in a patient in need thereof, comprising administering to the patient a therapeutically effective dose of a RTP801L inhibitor, thereby treating the neurodegenerative disease in the patient.
A method for treating or preventing a disease associated with ischemia or ischemia-reperfusion injury to a tissue in a patient in need thereof, comprising administering to the patient a therapeutically effective dose of a RTP801L inhibitor, thereby treating or preventing the disease in the patient.
A method for treating a disease associated with cell loss in a patient in need thereof, comprising administering to the patient a therapeutically effective dose of a RTP801L inhibitor, thereby treating the disease in the patient.
Dependencies are inferred from the claim text.